JERUSALEM, Jan. 6, 2025
/PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI)
("Scinai" or the "Company"), a biopharmaceutical company
specializing in inflammation and immunology (I&I) biological
products and offering CDMO services through its Scinai Bioservices
unit, announced today that its CEO, Mr. Amir Reichman, and Chairman of the Board, Mr.
Mark Germain, will attend the IATI
Mini Mixiii Conference in Miami,
FL on Jan 9, 2025 and the JP
Morgan HealthCare Conference week in San
Francisco from Jan 13-15,
2025. On Jan 14, 2025, Mr.
Reichman and Mr. Germain will also participate in the SIC Biotech
Symposium in San Francisco.
During these events, Mr. Reichman and Mr. Germain will hold
meetings with:
- Institutional and private investors interested in Scinai's
value proposition.
- Potential pharma partners in the inflammation & immunology
field interested in co-developing or in-licensing Scinai's
innovative NanoAbs.
- Prospective clients for the company's comprehensive biologics
CDMO services.
Interested parties are encouraged to schedule a meeting
through:
1) The Mini Mixiii conference partnering platform
2) The CSSi partnering system
3) Emailing Scinai at ir@scinai.com
The company has recently released a year-end video highlighting
the key accomplishments and achievements of 2024. To watch the
video, please click on the following
https://youtu.be/0YlY1uf5A64
About Scinai Immunotherapeutics
Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) is a
biopharmaceutical company with two complementary business units,
one focused on in-house development of inflammation and immunology
(I&I) biological therapeutic products beginning with an
innovative, de-risked pipeline of nanosized VHH antibodies
(nanoAbs) targeting diseases with large unmet medical needs, and
the other a boutique CDMO providing biological drug development,
analytical methods development, clinical cGMP manufacturing, and
pre-clinical and clinical trial design and execution services for
early stage biotech drug development projects.
Company website: www.scinai.com.
Company Contacts
Investor Relations | +972 8 930 2529
| ir@scinai.com
Business Development | +972 8 930 2529 | bd@scinai.com
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Litigation Reform Act of 1995. Words
such as "expect," "believe," "intend," "plan," "continue," "may,"
"will," "anticipate," and similar expressions are intended to
identify forward-looking statements. All statements, other than
statements of historical facts, are forward-looking
statements. These forward-looking statements reflect
management's current views with respect to certain current and
future events and are subject to various risks, uncertainties and
assumptions that could cause the results to differ materially from
those expected by the management of Scinai Immunotherapeutics Ltd.
Risks and uncertainties include, but are not limited to;
lower than anticipated revenues of Scinai's CDMO business;
the risk that Scinai's expanded presence in the U.S. will not
significantly enhance the prospects of its CDMO unit; the risk that
the Company will otherwise be unable to remain compliant with
the continued listing requirements of Nasdaq; failure to sign
agreements with other potential clients of the CDMO business; a
delay in the commencement and results of pre-clinical and clinical
studies, including the Phase 1/2a study for psoriasis, the risk of
delay in, Scinai's inability to conduct, or the unsuccessful
results of, its research and development activities, including the
contemplated in-vivo studies and a clinical trial; the risk that
Scinai will not be successful in expanding its CDMO business or
in-license other NanoAbs; the risk that Scinai may not be able to
secure additional capital on attractive terms, if at all; the risk
that the therapeutic and commercial potential of NanoAbs will not
be met or that Scinai will not be successful in bringing the
NanoAbs towards commercialization; the risk of a delay in the
preclinical and clinical trials data for NanoAbs, if any; the risk
that our business strategy may not be successful; Scinai's ability
to acquire rights to additional product opportunities; Scinai's
ability to enter into collaborations on terms acceptable to Scinai
or at all; timing of receipt of regulatory approval of Scinai's
manufacturing facility in Jerusalem, if at all or when required; the
risk that the manufacturing facility will not be able to be used
for a wide variety of applications and other vaccine and treatment
technologies; and the risk that drug development involves a lengthy
and expensive process with uncertain outcomes. More detailed
information about the risks and uncertainties affecting the Company
is contained under the heading "Risk Factors" in the Company's
Annual Report on Form 20-F filed with the Securities and Exchange
Commission ("SEC") on May 15, 2024,
and the Company's subsequent filings with the SEC. Scinai
undertakes no obligation to revise or update any forward-looking
statement for any reason.
Photo -
https://mma.prnewswire.com/media/2591208/Scinai_Immunotherapeutics.jpg
Logo
- https://mma.prnewswire.com/media/2310190/Scinai_Immunotherapeutics_Logo.jpg
View original content to download
multimedia:https://www.prnewswire.com/news-releases/scinai-to-connect-with-investors-and-pharma-leaders-at-upcoming-key-us-conferences-302342946.html
SOURCE Scinai Immunotherapeutics Ltd.
